Expect to See Crizanlizumab or Voxelotor for Some Sickle Cell Patients

Crizanlizumab (Adakveo, ah-DAK-vee-oh) and voxelotor (Oxbryta, oks-BRYE-tuh) will be new meds for sickle cell disease.

They may be added to hydroxyurea...the first-line option to reduce pain crises, hospitalizations, and possibly improve survival.

And they’ll compete with oral L-glutamine (Endari)...which seems to reduce pain crises and possibly hospitalizations.